Impact of body mass index on mortality in Swiss hospital patients with ST-elevation myocardial infarction: does an obesity paradox exist? by Witassek, Fabienne et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Impact of body mass index on mortality in Swiss hospital patients with
ST-elevation myocardial infarction: does an obesity paradox exist?
Witassek, Fabienne; Schwenkglenks, Matthias; Erne, P; Radovanovic, Dragana
Abstract: Unspecified
DOI: 10.4414/smw.2014.13986
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-98705
Published Version
Originally published at:
Witassek, Fabienne; Schwenkglenks, Matthias; Erne, P; Radovanovic, Dragana (2014). Impact of body
mass index on mortality in Swiss hospital patients with ST-elevation myocardial infarction: does an
obesity paradox exist? Swiss Medical Weekly, 144:w13986. DOI: 10.4414/smw.2014.13986
Original article | Published 7 August 2014, doi:10.4414/smw.2014.13986
Cite this as: Swiss Med Wkly. 2014;144:w13986
Impact of Body Mass Index on mortality in Swiss
hospital patients with ST-elevation myocardial
infarction: does an obesity paradox exist?
Fabienne Witasseka, Matthias Schwenkglenksb, Paul Ernec,d, Dragana Radovanovica
a AMIS Plus Data Centre1, Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland
b Health Economics Unit, Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland
c Klinik St. Anna, Lucerne, Switzerland
d Cardiology Clinic, University Hospital Zurich, Zurich, Switzerland
1 Collaborators
AMIS Plus Participants 2005–2012: The authors would like to express
their gratitude to the teams of the following hospitals (listed in
alphabetical order with the names of the local principal investigators):
Aarau, Kantonsspital (P Lessing); Affoltern am Albis, Spital (F Hess);
Altdorf, Kantonsspital (R Simon); Baden, Kantonsspital (U
Hufschmid); Basel, St. Claraspital (B Hornig); Bern, Beau-Site Klinik
(S Trummler);Bern, Inselspital (S Windecker); Bern, Tiefenauspital (P
Loretan); Biel, Spitalzentrum (C Roethlisberger); Bülach, Spital (G
Mang); Burgdorf, Regionalspital Emmental (D Ryser); Davos, Spital
(W Kistler); Dornach, Spital (T Hongler); Einsiedeln, Regionalspital
(S Stäuble); Flawil, Spital (G Freiwald); Frauenfeld, Kantonsspital
(HP Schmid); Fribourg, Hôpital cantonal (JC Stauffer/S Cook);
Frutigen, Spital (K Bietenhard); Genève, Hôpitaux universitaires (M
Roffi); Grenchen, Spital (R Schönenberger); Herisau, Kantonales
Spital (M Schmidli); Horgen, See Spital (B Federspiel); Interlaken,
Spital (EM Weiss); Kreuzlingen, Herzzentrum Bodensee (K Weber);
Lachen, Regionalspital (I Poepping); Langnau im Emmental,
Regionalspital (A Hugi); Laufenburg, Gesundheitszentrum Fricktal (E
Koltai); Lugano, Cardiocentro Ticino (G Pedrazzini); Luzern,
Kantonsspital (P Erne); Männedorf, Kreisspital (T Heimes);
Mendrisio, Ospedale regionale (A Pagnamenta); Meyrin, Hôpital de la
Tour (P Urban); Moutier, Hôpital du Jura bernois (C Stettler);
Münsingen, Spital (F Repond); Münsterlingen, Kantonsspital (F
Widmer); Muri, Kreisspital für das Freiamt (C Heimgartner); Nyon,
Group. Hosp. Ouest lémanique (R Polikar); Olten, Kantonsspital (S
Bassetti); Rheinfelden, Gesundheitszentrum Fricktal (HU Iselin);
Rorschach, Spital (M Giger); Sarnen, Kantonsspital Obwalden (T
Kaeslin); Schaffhausen, Kantonsspital (A Fischer); Schlieren, Spital
Limmattal (T Herren), Scuol Ospidal d’Engiadina Bassa (C
Neumeier/G Flury); Solothurn, Bürgerspital (R Vogel); Stans,
Kantonsspital Nidwalden (B Niggli); St. Gallen, Kantonsspital (H
Rickli); Sursee, Luzerner Kantonsspital (J Nossen); Thun, Spital (U
Stoller); Uster, Spital (E Bächli); Wetzikon, GZO Spital (U Eriksson);
Winterthur, Kantonsspital (T Fischer), Wolhusen, Luzerner
Kantonsspital (M Peter); Zofingen, Spital (S Gasser); Zollikerberg,
Spital (R Fatio); Zürich, Hirslanden Klinik im Park (O Bertel); Zürich,
Universitätsspital (M Maggiorini); Zürich, Stadtspital Triemli (F
Eberli); Zürich, Stadtspital Waid (S Christen).
Summary
BACKGROUND: The obesity paradox refers to the phe-
nomenon that obese patients seem to have a better outcome
than normal weight patients in a variety of disease condi-
tions. The aim of this study was to investigate the impact of
Body Mass Index (BMI) on mortality in patients with ST-
elevation myocardial infarction (STEMI) who underwent
percutaneous coronary intervention (PCI).
METHODS: Between January 2005 and July 2012, the
Swiss AMIS Plus registry enrolled 6,938 patients with
acute STEMI who underwent PCI. These patients were
stratified into 5 BMI groups according to the classification
system of the World Health Organisation. The odds for in-
hospital mortality according to BMI groups were analysed
using logistic regression with normal weight patients as the
reference.
RESULTS: Crude in-hospital mortality rates showed a U-
shaped distribution between BMI groups, with the lowest
mortality in obese class I patients (2.0%) and the highest
mortality in underweight patients (9.0%). The odds for in-
hospital mortality were significantly lower for obese class
I (OR 0.56; 95% CI 0.35–0.91) and significantly higher for
underweight patients (OR 2.72; 95% CI 1.14–6.48) com-
pared to the normal weight group and odds ratios showed a
U-shaped distribution. After adjustment for covariates, the
odds ratios maintained a U-shape distribution albeit the dif-
ferences between BMI groups were no longer significant.
CONCLUSION: This study showed that the lower crude
in-hospital mortality of obese class I patients can be partly
explained by lower age and lower co-morbidity rates.
Abbreviations
ACS Acute coronary syndrome
AMIS Acute myocardial infarction in Switzerland
ANOVA Analysis of variance
BMI Body Mass Index
CI Confidence interval
MI Myocardial infarction
OR Odds ratio
PCI Percutaneous coronary intervention
ROC Receiver operating curve
STEMI ST-elevation myocardial infarction
WHO World Health Organisation
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However, further studies are needed to investigate favour-
able factors associated with class I obesity.
Key words: obesity paradox; myocardial infarction;
percutaneous coronary intervention
Introduction
The observation that obese patients seem to have better out-
comes than normal weight patients in a variety of disease
conditions is known as “the obesity paradox” [1–3]. In the
context of acute coronary syndromes (ACSs), some studies
found a reduced short- or long-term mortality in obese pa-
tients after an acute event [4–6] although obesity is causally
linked to several adverse effects, such as insulin resistance,
dyslipidaemia and increased systemic inflammation [7]. It
was therefore suggested that obesity may have protective
effects in patients with ACS [8]. Careful verification is re-
quired given the well-known role obesity plays as a risk
factor for developing cardiovascular diseases, still the most
common cause of death worldwide [9].
Conflicting results are available on the obesity paradox
in hospitalised patients with ST-elevation myocardial in-
farction (STEMI) who underwent PCI. Previous studies
showed a lower in-hospital mortality rate for obese patients
but the significant negative relationship was attenuated by
correcting for confounders [10–12], thus weakening the
hypothesis that obesity may be an independent protection
factor in this patient group. However, a meta-analysis that
combined the results of five observational cohort studies
supported the hypothesis that overweight and obesity have
a significant protective effect [13]. Therefore, it is still
not clearly understood whether the paradoxical relationship
between obesity and mortality is causal or not and only lim-
ited data are available.
The aim of this study was to investigate the impact of Body
Mass Index (BMI) on in-hospital mortality in Swiss pa-
tients who suffered a STEMI and underwent PCI, and to
assess if confounding factors may explain the obesity para-
dox.
Methods
The analysis was based on data from the AMIS Plus re-
gistry, an on-going nationwide prospective registry of pa-
tients admitted with ACS to hospitals in Switzerland. Since
January 1997, the AMIS Plus registry collects data on pa-
tients with acute myocardial infarction (AMI) who are hos-
pitalised and treated in Swiss hospitals. Details have been
previously published [14, 15]. The participation of hos-
pitals is voluntary and since 1997, 82 hospitals, ranging
from community-level institutions to large tertiary facilit-
ies, have been collecting temporarily or continuously data
for AMIS Plus. The registry has been approved by the
Supra-Regional Ethics Committee for Clinical Studies, the
Swiss Board for Data Security, and the Cantonal Ethics
Commissions.
For this analysis, patients enrolled between 1 January 2005
and 9 July 2012 with a discharge diagnosis of STEMI were
included. In AMIS Plus, STEMI is defined by characterist-
ic symptoms, ST-elevation and/or new left bundle branch
block on the initial ECG, and total creatine kinase or cre-
atine kinase MB fraction at least twice the upper limit of
normal or troponin I or T above individual hospital cut-
off levels for AMI. Patients with missing BMI data were
excluded. The analysis was limited to patients who under-
went PCI in order to reduce biases due to different thera-
peutic and reperfusion strategies. Patients were stratified
into BMI groups according to the international classifica-
tions of the World Health Organisation (WHO) [16]: under-
weight (BMI <18.5 kg/m2), normal weight (BMI 18.5–24.9
kg/m2), overweight (BMI 25–29.9 kg/m2), obese class I
(BMI 30–34.9 kg/m2), obese class II (BMI 35–39.9 kg/m2)
and obese class III (BMI ≥40 kg/m2). As only 85 patients
were in obese class III, obese class II and obese class III
were combined into one group so that in the end only five
BMI groups were used for analysis.
The endpoint of interest was in-hospital mortality; cardiac
and non-cardiac causes of death were included. Covariate
selection was based on prior knowledge – for example
known risk factors for cardiovascular disease were in-
cluded [17]. All covariates are listed in table 1. BMI was
calculated using height and weight at admission and treated
in the analysis as a categorical variable as described above.
Age was used as a continuous variable. All other covariates
were dichotomous. Of the risk factors considered, diabetes
mellitus, arterial hypertension and dyslipidaemia were as-
sumed to be present if the patient had previously been
treated and/or diagnosed by a physician. Documentation of
risk factors was accepted as provided by the treating hos-
pital. Family history of ischaemic heart disease was defined
as the presence of ischaemic heart disease in a first-degree
relative younger than 60 years. History of coronary artery
disease was defined as a report of previous angina pector-
is and/or myocardial infarction. A patient was defined as
a current smoker if he had smoked at least 100 cigarettes
in his life and was currently smoking. Co-morbidities were
assessed using the Charlson Index [18]. Description of
acute clinical status at admission was based on the need for
resuscitation prior to admission, presence of atrial fibrilla-
tion and Killip class (≤ 2 versus >2). Multivessel disease
was regarded as being present if the angiography during
hospitalisation identified more than one involved vessel.
Statistics
Discrete variables are presented as frequencies and the
Pearson chi-square test was used to compare frequencies
between BMI groups. Continuous variables are described
as means (standard deviation [SD]) and analysis of vari-
ance or the Kruskal-Wallis test were used to compare BMI
group differences for normally distributed and non-nor-
mally distributed variables, respectively.
Logistic regression analysis was used to assess univariate
associations between in-hospital mortality and BMI groups
or covariates, as well as for multivariate analysis. For the
unadjusted and adjusted analyses, BMI groups were
entered as categorical variables and normal weight was set
as the reference category. All available covariates were in-
cluded in the multivariate model if they showed a p-value
<0.2 in the univariate analysis. The Hosmer-Lemeshow
goodness of fit test was used to assess model fit and receiv-
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er operating characteristic (ROC) curve analysis was used
to determine the discrimination power of the model.
For all statistical analyses SPSS (Chicago, Illinois, USA)
for Windows XP (version 20.0) was used. A p-value ≤0.05
was considered to indicate statistical significance for all
tests.
Results
Patient population and characteristics
Between 1 January 2005 and 9 July 2012, 18,525 patients
with ACS were enrolled in the AMIS Plus registry. From
the 9,949 patients classified as having STEMI, 7,891 pa-
tients underwent PCI. Of these, 6,938 (87.9%) patients
with valid data on BMI were included in the analysis. The
mean (SD) age of the patients included was 62.8 (12.5)
years; the age range was 19.2 to 97.8 years and 77.1% of
them were male. According to the defined BMI groups,
67 patients (1%) were underweight, 2294 (33.1%) were
of normal weight, 3123 (45.0%) were overweight, 1105
(15.9%) had class I-obesity and 349 (5%) had class II/III-
obesity.
Table 1 shows patient characteristics on admission and an-
giographic findings for BMI groups. With increasing BMI,
patients were younger and more likely to be diabetic and
dyslipidaemic. The occurrence of arterial hypertension also
increased with increasing BMI, except for underweight pa-
tients who were more likely to be hypertensive than normal
weight patients. The underweight group had the highest
prevalence for moderate to severe renal disease, peripheral
vascular disease as well as cardiac insufficiency. Propor-
tions of patients with history of coronary artery disease or
cancer did not differ significantly between BMI groups.
There was also no significant difference in the percentage
of patients with Killip class >2 or atrial fibrillation at ad-
mission and the need for resuscitation prior to admission
was similar in all groups. Angiographic findings did not
show significant differences in the prevalence of mul-
tivessel disease.
Table 1: Admission characteristics and angiographic data according to BMI.
BMI groups
Underweight Normal weight Overweight Obese class I Obese class II/
III
p-value
Number of patients n 67 2294 3123 1105 349
Male n (%) 20 (29.9) 1630 (71.1) 2576 (82.5) 888 (80.4) 236 (67.6) <0.001
Age in years mean (SD) 67.8 (13.9) 64.2 (13.2) 62.7 (12.0) 60.7 (11.9) 60.9 (12.2) <0.001
range 32.1–88.9 21.8–97.8 23.9–94.9 19.2–88.9 24.4–86.8
BMI [kg/m2] mean (SD) 17.4 (0.8) 23.0 (1.5) 27.2 (1.4) 31.9 (1.4) 38.6 (3.8) <0.001
range 14.6–18.4 18.5–24.9 25.0–29.9 30.0–34.9 35.0–61.6
History of coronary artery disease n (%) 11/66 (16.7) 589/2274 (25.9) 866/3080 (28.1) 285/1088 (26.2) 90/346 (26.0) 0.116
Risk factors
Diabetes mellitus n (%) 6/62 (9.7) 224/2206 (10.2) 456/3010 (15.1) 252/1064 (23.7) 130/337 (38.6) <0.001
Arterial hypertension n (%) 35/67 (52.2) 1058/2163 (48.9) 1586/2945 (53.9) 702/1058(66.4) 258/334 (77.2) <0.001
Dyslipidaemia n (%) 21/61 (34.4) 874/2025 (43.2) 1402/2748 (51.0) 515/968 (53.2) 183/307 (59.6) <0.001
Current smoker n (%) 33/55 (60.0) 980/2100 (46.7) 1213/2858 (42.4) 480/1024 (46.9) 132/324 (40.7) 0.001
Family history n (%) 10/57 (17.5) 639/1978 (32.3) 942/2716 (34.7) 341/960 (35.5) 94/302 (31.1) 0.018
Co-morbidities
Cancer n (%) 5/65 (7.7) 113/2247 (5.0) 142/3042 (4.7) 39/1082 (3.6) 10/341 (2.9) 0.134
Moderate to severe renal disease n (%) 12/65 (18.5) 103/2247 (4.6) 101/3042 (3.3) 34/1082 (3.1) 15/341 (4.4) <0.001
Peripheral vascular disease (ST III/IV) n (%) 9/65 (13.8) 65/2247 (2.9) 76/3042 (2.5) 35/1082 (3.2) 17/341 (5.0) <0.001
Cardiac insufficiency (NYHA III/IV) n (%) 5/65 (7.7) 34/2247 (1.5) 42/3042 (1.4) 15/1082 (1.4) 10/341 (2.9) <0.001
Resuscitation prior to admission n (%) 3/67 (4.5) 148/2294 (6.5) 174/3123 (5.6) 57/1105 (5.2) 17/349 (4.9) 0.451
Killip class
Killip class >2 n (%) 7/67 (10.4) 156/2276 (6.9) 178/3102 (5.7) 62/1103 (5.6) 22/346 (6.4) 0.235
Heart rhythm
Atrial fibrillation n (%) 3/67 (4.5) 64/2294 (2.8) 84/3121 (2.7) 36/1105 (3.3) 12/349 (3.4) 0.730
Angiographic findings
Multi vessel disease n (%) 38/63 (60.3) 1284/2272 (56.5) 1803/3100 (58.2) 613/1094 (56.0) 200/347 (57.6) 0.648
BMI, Body Mass Index
Table 2: In-hospital death and complications according to BMI.
BMI groups
Underweight Normal weight Overweight Obese class 1 Obese class II/
III
p-value
In-hospital death n (%) 6/67 (9.0) 80/2294 (3.5) 94/3123 (3.0) 22/1105 (2.0) 15/349 (4.3) 0.005
Reinfarction n (%) 0/67 (0.0) 22/2294 (1.0) 19/3122 (0.6) 9/1104 (0.8) 3/349 (0.9) 0.602
Cerebrovasc. event n (%) 0/67 (0.0) 17/2294 (0.7) 20/3122 (0.6) 7/1104 (0.6) 3/349 (0.9) 0.930
Cardiogenic shock n (%) 6/67 (9.0) 95/2294 (4.1) 98/3122 (3.1) 32/1104 (2.9) 19/349 (5.4) 0.006
BMI, Body Mass Index
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Clinical outcomes
Of the 6,938 patients, 217 (3.1%) died during hospitalisa-
tion. The mortality rate was higher in females (3.7%) than
in males (3.0%) but the difference was not significant (p =
0.171). In-hospital mortality differed significantly between
BMI groups (p = 0.005). It showed a U-shaped distribution
with the lowest mortality in patients with class I obesity
(2.0%) and the highest mortality in underweight patients
(9.0%) (table 2).
Table 2 shows the occurrence of complications during hos-
pitalisation by BMI group. The occurrence of re-infarction
and cerebrovascular events did not differ between the
groups. In contrast, the occurrence of cardiogenic shock
during hospitalisation differed significantly (p = 0.006)
between BMI groups; it was highest in underweight (9.0%)
and class II/III-obese (5.4%) patients.
Analysis of in-hospital mortality according to BMI
group
Overall, BMI groups were significantly associated with in-
hospital mortality (p = 0.008) in the unadjusted analysis.
In relation to the normal weight category, the odds for in-
hospital mortality were significantly lower for patients with
obesity class I (OR 0.56; 95% CI 0.35–0.91) and signific-
antly higher for underweight patients (OR 2.72; 95% CI
1.14–6.48). The odds for overweight and obese class II/III
patients did not differ significantly from the normal weight
category (fig. 1a). The ORs for all BMI groups indicated
a U-shaped relationship of BMI and in-hospital mortality
(fig. 1a).
After statistical adjustment, BMI groups were no longer
significantly associated with in-hospital mortality (p =
0.224). The odds for in-hospital mortality of the under-
weight, overweight, obese class I and obese class II/III pa-
tients did not differ significantly from the odds of the nor-
mal weight group but a U-shaped relationship was still
visible (fig. 1b).
As visible in table 3, the strongest independent predictors
of in-hospital mortality in the multivariate model were age
per additional year (OR 1.06; 95% CI 1.04–1.09), history
of diabetes (OR 2.15; 95% CI 1.37–3.38), moderate to
severe renal disease (OR 2.32; 95% CI 1.28–4.21), resus-
citation prior to admission (OR 5.58; 95% CI 3.40–9.18)
and Killip class >2 (OR 8.01; 95%CI 5.18–12.37). All
these covariates showed a positive significant association
with in-hospital mortality whereas the other covariates did
not show a significant impact in the multivariate analysis.
The Hosmer-Lemeshow goodness of fit test showed no sig-
nificance (p = 0.505), indicating that the predicted values
of the model do not differ significantly from the observed
values. The ROC analysis showed an area under the curve
of 0.877 (p = 0.001; 95%CI 0.85–0.91) indicating excellent
discriminatory power of the model.
Discussion
This study showed that an apparent obesity paradox in
Swiss patients with acute STEMI who underwent PCI can
be, at least partly, explained by confounders. The descript-
ive analysis showed a U-shaped distribution of the crude
in-hospital mortality rate across BMI groups with the low-
est mortality in class I obese patients. Unadjusted logistic
regression analysis indicated that obesity class I patients
were significantly less likely and underweight patients sig-
nificantly more likely to die during hospitalisation com-
pared with normal weight patients. However, after adjust-
ment for covariates these differences between BMI groups
were substantially reduced and BMI group was no longer a
Table 3: Adjusted effects on in-hospital mortality (logistic regression model, N = 5,400).
Variables B OR (95% CI) p
BMI groups – 0.224
Underweight 0.970 2.64 (0.77–9.02) 0.122
Normal weight – 1 –
Overweight 0.047 1.05 (0.68–1.62) 0.831
Obese class I –0.503 0.61 (0.30–1.23) 0.167
Obese class II/III 0.295 1.34 (0.61–2.98) 0.468
Female 0.082 1.09 (0.70–1.67) 0.709
Age (per additional year) 0.062 1.06 (1.04–1.09) <0.001
History of coronary artery disease 0.286 1.33 (0.86–2.05) 0.194
Diabetes mellitus 0.766 2.15 (1.37–3.38) 0.001
Arterial hypertension –0.157 0.86 (0.55–1.33) 0.489
Dyslipidaemia –0.126 0.88 (0.59–1.33) 0.547
Current smoker –0.011 0.99 (0.62–1.59) 0.964
Cancer 0.563 1.76 (0.93–3.32) 0.083
Moderate to severe renal disease 0.843 2.32 (1.28–4.21) 0.005
Peripheral vascular disease (ST III/IV) –0.120 0.89 (0.36–2.16) 0.792
Cardiac insufficiency (NYHA III/IV) 0.419 1.52 (0.64–3.60) 0.340
Resuscitation prior to admission 1.720 5.58 (3.40–9.18) <0.001
Killip class >2 2.080 8.01 (5.18–12.37) <0.001
Constant –8.833 <0.001
BMI, Body Mass Index. OR, Odds Ratio
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significant predictor of in-hospital mortality in this specific
patient population.
Therefore, even if this study revealed a U-shaped associ-
ation between BMI and crude in-hospital mortality with
best outcome for class I obese patients, it remains unclear
how much BMI directly contributes to this protective effect
and it seems that at least a part of the obesity paradox can
be explained by covariates. These findings are in line with
previous studies, which investigated the obesity paradox
in patients hospitalised for STEMI [11, 12, 19]. Studies
that focused, as this study, on PCI-treated patients showed
an attenuation of an inverse association between BMI and
in-hospital mortality after adjustment for confounders [10,
20, 21]. A meta analysis of five observational cohort stud-
ies supported a significant protective effect of overweight
and obesity [13] but the included studies did not all use
the WHO classification system for BMI and correction for
confounders may be different in all these studies. Many
other studies focused on the association of BMI and long-
term mortality after PCI. In 2006, a meta analysis of cohort
studies with follow ups between one to five years showed a
clear U-shaped distribution of the adjusted relative risks for
mortality among BMI groups for PCI patients, but only the
underweight group showed a significant difference com-
pared to the normal weight patients [22]. However, in the
ensuing years, several studies strengthened the hypothesis
Figure 1
a: Unadjusted odds ratios with 95% CI for in-hospital mortality by
BMI categories with normal weight patients as the reference. The
odds for in-hospital mortality were significantly higher for
underweight and significantly lower for obese class I patients. OR,
Odds Ratio. CI, Confidence Interval.
b: Adjusted odds ratios with 95% CI for in-hospital mortality by BMI
categories with normal weight patients as the reference. None of
the BMI groups differed significantly in the odds for in-hospital
mortality compared with normal weight patients. OR, Odds Ratio.
CI, Confidence Interval.
that higher BMI brings a direct protective long-term effect
in patients treated with PCI [8, 23, 24]. In general, it is dif-
ficult to evaluate the effect of obesity on mortality as not
only are there multiple factors that influence mortality but
also because only observational data can be used to address
this question. The variation in the choice of confounders
used in studies may explain the discrepant results on this
topic.
In our study, obese class I patients were younger and had
a lower renal disease rate than the other BMI groups. In
the multivariate model, these two factors were independent
predictors of in-hospital mortality and may therefore
provide a partial explanation for the favourable mortality
outcome in this group. In previous studies, age and persist-
ing renal disease were also important factors attenuating
the association of BMI and in-hospital mortality [10, 21]
A recent study which investigated the impact of age on the
prognostic value of BMI suggested that the obesity paradox
should possibly be age-contextualised as they found that
BMI only influenced mortality in patients <75 years [25].
The strongest predictor of in-hospital mortality in our pa-
tient sample was a Killip class >2. The occurrence of this
risk factor was again lowest in the obese class I patients. On
the other hand, obesity class I patients were more likely to
have diabetes compared to the groups with lower BMI and
this was shown in the multivariate model to significantly
worsen the prognosis. Arterial hypertension and dyslipid-
aemia, two well-known risk factors for arteriosclerosis and
AMI and often present in obese patients, seemed to have no
significant influence on in-hospital mortality after STEMI.
The fact that not all studies work with the same BMI clas-
sification system makes it difficult to compare results. The
question arises whether the WHO classification used here
is ideal for investigating the topic studied. According to
the WHO, normal weight includes patients with a BMI
between 18.5–24.9 kg/m2, a range which may include
severely ill persons in the lower part. Several co-morbidit-
ies or chronic disease states are related to low body weight
[26] and a low BMI may reflect an increased metabolic
demand, catabolic or inflammatory state, or a generally
poorer health condition. Critical voices hold that in studies
using a BMI range of 18.5–<25 kg/m2 for normal weight,
the mortality in the normal weight group may thus be in-
creased, leading to an apparent protective effect of a high-
er BMI [27]. However, an additional multivariate logist-
ic regression analysis where we excluded patients with a
BMI below 20 kg/m2 showed minimal changes in the odds
ratios of BMI groups and all other covariates (data not
shown). The underweight group in this study had an in-
creased crude in-hospital mortality compared with the nor-
mal weight group but the relationship became non-signi-
ficant after adjustment, probably due to the low number of
patients in the underweight group.
The use of registry data implies some inevitable limita-
tions. As only hospitalised patients are registered, there
may be a survival bias and it is not possible to characterise
the fraction of patients who die before reaching hospital.
The fact that hospitals are not obliged to include all their
patients with AMI may lead to additional selection effects.
A further limitation is that the data on height and weight to
calculate BMI might be rather anamnestic instead of meas-
Original article Swiss Med Wkly. 2014;144:w13986
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ured in the case of most patients. Furthermore, the analys-
is is limited to the variables which are registered and po-
tentially important factors may not be taken into account,
such as for example compliance with medical treatment,
cardiorespiratory fitness of patients or the differentiation
between fat mass and lean mass. A study which investig-
ated the impact of lean mass index and body fat on survival
of patients with coronary heart disease found that, within
three years, mortality was inversely related with lean mass
index and body fat [28]. Therefore, further studies taking
into account the body composition might provide an inter-
esting basis for investigating if adipose tissue, now recog-
nised as an endocrine organ [29], brings a direct protective
effect.
An important strength of this study is that the analysis was
performed with a well-defined study population as only
PCI- treated patients were included. The exclusion of pa-
tients registered before 2005 reduced the influence of tech-
nical progress, changes in clinical management, and qual-
ity, which have improved over the years.
To our knowledge this is the first study to investigate the
obesity paradox in patients with STEMI in Switzerland and
may contribute to a better understanding of the risk pro-
file of a patient after AMI. Further studies are needed to
investigate the reasons for lower mortality in obese pa-
tients, which may have implications for the treatment of
BMI groups at higher risk.
Conclusion
This study showed a persistent U-shaped association
between in-hospital mortality rates and BMI groups in pa-
tients with STEMI who underwent PCI in Switzerland with
the lowest mortality in patients with obesity class I.
However, the differences between BMI groups were not
significant after correction for covariates. Lower age of
obese patients when suffering an AMI seems to partly ex-
plain the obesity paradox and simultaneously underlines
the importance of prevention for young, obese patients to
reduce the risk of AMI at a young age. Other factors such
as differences in medical treatment, absence of co-morbid-
ities or direct protective effects of adipose tissue may addi-
tionally influence post-PCI mortality and should be studied
further to fully understand the impacts responsible for the
lower mortality in moderately obese patients.
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Figures (large format)
Figure 1
a: Unadjusted odds ratios with 95% CI for in-hospital mortality by BMI categories with normal weight patients as the reference. The odds for in-
hospital mortality were significantly higher for underweight and significantly lower for obese class I patients. OR, Odds Ratio. CI, Confidence
Interval.
b: Adjusted odds ratios with 95% CI for in-hospital mortality by BMI categories with normal weight patients as the reference. None of the BMI
groups differed significantly in the odds for in-hospital mortality compared with normal weight patients. OR, Odds Ratio. CI, Confidence Interval.
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